Trial Profile
Phase II study of liposomal doxorubicin in combination with trastuzumab plus cyclophosphamide followed by docetaxel plus trastuzumab as primary systemic therapy for patients with locally advanced breast cancer with HER2 overexpression or amplification.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2018
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Docetaxel; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms MYETT
- 26 Feb 2018 New trial record